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Abstract
Objective The maximal standardized uptake value
(SUVmax) of pulmonary lesions on dual-time-point (DTP)
fluorodeoxyglucose positron emission tomography (FDG-
PET) has been shown to be useful for differentiation
between malignant and non-malignant pulmonary lesions,
and also to be of value for intrathoracic nodal staging of
non-small cell lung cancer (NSCLC). However, a few
NSCLC lesions have been found to show decreased FDG
uptake on delayed images, and the significance of this
finding remains unknown.
Patients and methods We conducted a retrospective
review of the data of 284 patients with NSCLC who
underwent DTP FDG-PET before surgery. Cases of ade-
nocarcinoma in situ and minimally invasive adenocarci-
noma were excluded, because these lesions show little
FDG uptake. Each patient was scanned at 60 min (early
acquisition; SUV-E) and 115 min (delayed acquisition;
SUV-D) after the radiopharmaceutical injection. The
intratumoral retention index (RI) of 18F-FDG was mea-
sured for each examination by the DTP method. Recur-
rence-free survival (RFS) was determined by the Kaplan–
Meier method and compared in relation to the SUV-E,
SUV-D, and RI by univariate and multivariate analysis
using models including the clinico-pathological prognostic
factors.
Results Of the 284 cases, the RI B 0 was in 49 cases
(17.3 %). This group of patients showed lower values of
SUV-E and SUV-D, a smaller tumor size, and a lower rate
of lymphatic invasion or vascular invasion. It was partic-
ularly noteworthy that lymph node metastasis was not
histopathologically confirmed in any of these patients.
Univariate analysis identified the RI, SUV-E and SUV-D,
besides age, tumor size, lymph node metastasis, and tumor
differentiation grade as predictors of the RFS. On the other
hand, multivariate analysis identified the RI and lymph
node metastasis, but not the SUV-E and SUV-D, as inde-
pendent predictors of the RFS.
Conclusions This study demonstrated that DTP FDG-
PET of the primary tumor in NSCLC can be useful to
predict the RFS of the patients. In addition, this method
may also be useful to predict the presence/absence of
intrathoracic lymph node metastasis in these patients.
Keywords Non-small cell lung cancer  Lymph node
metastasis  Dual-time-point imaging 18F-FDG PET 
Retention index
Introduction
Fluorodeoxyglucose positron emission tomography (FDG-
PET) has become an important tool for the diagnosis and
staging of non-small cell lung cancer (NSCLC) [1]. The
maximal standardized uptake values (SUVmax) on FDG-
PET is calculated as the ratio of the activity in the tissue
per unit volume to the injected dose by body weight, and is
widely used because of the simplicity of its measurement
[2]. In NSCLC patients, the SUVmax values of the primary
tumors have been known to be correlated with the disease
stage, nodal status, histological type, tumor differentiation
grade, and rate of progression of the tumors [3–5]. In
addition, high SUVmax values have been reported as being
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among the poor prognostic factors in patients with NSCLC
[5–7].
Several studies have reported that determination of the
SUVmax of pulmonary lesions on dual-time-point (DTP)
FDG-PET is useful for differentiation between malignant
and non-malignant pulmonary lesions [8–10]. Moreover,
several investigators have shown that determination of the
SUVmax of the lymph nodes on DTP FDG-PET improved
the diagnostic ability of this imaging modality for
intrathoracic nodal staging in NSCLC patients [11–13]. In
general, most malignant lesions, including primary tumors
and lymph nodes, also show increased FDG uptake on the
delayed-phase images.
However, it has been reported that some NSCLC lesions
actually show decreased FDG uptake on the delayed-phase
images [14]. The significance of such decreased FDG
uptake of NSCLC lesions remains unknown. In the present
study, we analyzed the diagnostic impact of DTP FDG-
PET for intrathoracic nodal staging and also its prognostic
impact in patients with resectable NSCLC.
Patients and methods
Study population
We conducted this retrospective study in a total of 284
patients, who had undergone DTP FDG-PET before sur-
gery, which consisted of surgical resection with lymph
node dissection or sampling, at the Kawasaki Medical
School Hospital between 2007 and 2013. None of the
patients had received either radiotherapy or chemotherapy
prior to the surgery. The TNM stage was determined
according to the revised criteria published in 2009. The
histological diagnosis of the tumors was based on the cri-
teria of the IASLC/ATS/ERS proposed in 2011 [15]. Cases
of adenocarcinoma in situ and minimally invasive adeno-
carcinoma were excluded, because these lesions show little
uptake of FDG [16]. This study was conducted with the
approval of the institutional Ethics Committee of Kawasaki
Medical School (No.1323). Follow-up information until
either recurrence or December 2014 was obtained from the
medical records.
Fdg-pet
All PET/CT examinations were performed with a dedicated
PET/CT scanner (Discovery ST Elite; GE Healthcare,
Japan). The axes of the multidetector CT and PET systems
were mechanically aligned so that the patient could be
moved from the CT to the PET scanner gantry by simply
changing the position of the examination table. The
resultant PET and CT scans were coregistered with
hardware. PET/CT scanning was performed at 60 and
115 min after the intravenous injection of 150–220 MBq of
18FDG (FDGscan, Universal Giken, Nihon Mediphysics,
Tokyo, Japan). The regions of interest (ROI) were placed
three-dimensionally over the lung cancer nodules. Semi-
quantitative analysis of the images was performed by
measuring the SUVmax of the lesions. The SUVs were
calculated using the following equation: tumor activity
concentration/(injected dose/body weight). Therefore, the
SUVmax measurements of the primary tumor were
obtained both on early- (SUV-E) and delayed scans (SUV-
D). In this study, we analyzed the ‘‘no integration of FDG’’
as ‘‘zero’’. In addition, all the cases with SUV-E value of
zero also had SUV-D value of zero. Furthermore, we cal-
culated the retention index (RI) from the SUVmax values
by the following formula: RI (%) = (SUV-D-SUV-E)/
SUV-E 9 100 when SUV-E[ 0, and RI (%) = 0 when
SUV-E = 0. RI is really impossible calculation with SUV-
E and SUV-D value of zero, therefore, we considered the
value as zero.
Statistical analysis
Statistical analysis was performed for examining the sig-
nificances of differences and the possible correlations
between the RI on DTP FDG-PET, and the clinicopatho-
logical features; Fisher’s exact test or the v2 test was used,
as appropriate. An unpaired t test was used for comparison
of continuous data. The prognostic evaluation was based on
the recurrence-free survival (RFS). RFS was defined as the
time from the date of surgery until lung cancer recurrence
or non–lung cancer death. The survival curves were esti-
mated using the Kaplan–Meier method, and differences
among the curves were evaluated by the log-rank test.
Univariate and multivariate analysis were performed using
Cox proportional hazard models. All the statistical analyses
were conducted using the SPSS software (Version 17.0;
SPSS Incorporation, Chicago, IL). All statistical tests were
two-sided, and probability values of\0.05 were regarded
as denoting statistical significance.
Results
Clinical characteristics
The characteristics of the patients are summarized in
Table 1. The patients ranged in age from 37 to 83 years
(mean, 70.4), and there were 195 men and 89 women. The
majority of patients (184, 64.8 %) had adenocarcinoma,
while 71 (25.0 %) had squamous cell carcinoma, 16
(5.6 %) had large cell carcinoma, and 13 (4.6 %) had other
histological types. Pathological N0 disease was confirmed
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in 230 patients (81.0 %), and N1 or N2 disease in 54
patients (19.0 %). The median follow-up period was
33.9 months (range 5–72 months).
Pathological characteristics in relation to the SUV-
E, SUV-D, and the RI
Table 2 shows the SUV-E, SUV-D and RI values in rela-
tion to the pathological findings. The mean SUV-E was 7.3
(range 0–30.7) and the mean SUV-D was 8.9 (range
0–35.7). In relation to the histological type, the SUV-E and
-D values were significantly higher in the non-adenocar-
cinoma group than in the adenocarcinoma group. The
SUV-E and -D values were significantly higher in cases
with a large tumor sizes ([31 mm), moderate or poor
tumor differentiation grade, and pathological lymph node
metastasis, lymphatic invasion, or vascular invasion, than
in those with small tumor sizes (\30 mm), well-differen-
tiated tumors, and no pathological lymph node metastasis,
lymphatic invasion, or vascular invasion. The mean RI was
21.1 % (range -23.1 to 214.0 %). The RI values were
significantly higher in the cases with non-adenocarcino-
mas, moderate or poor tumor differentiation grade, and
pathological lymph node metastasis, or vascular invasion
than in those with adenocarcinoma, well-differentiated
tumors, and no pathological lymph node metastasis or
vascular invasion.
Clinicopathological characteristics in relation
to the RI
We categorized the 284 patients according to the RI:
RI B 0 (Group A; n = 49: 17.3 %) or RI[ 0 (Group B;
n = 235). Group A had lower SUV-E (p\ 0.001) and
SUV-D (p\ 0.001) values, a smaller tumor size
(p = 0.001), well differentiation tumor grade (p = 0.001),
and a smaller percentages of patients with lymph node
metastasis (p = 0.001), pleural invasion (p\ 0.001),
lymphatic invasion (p\ 0.001), and vascular invasion
(p\ 0.001) than Group B, while no significant association
was observed with the age (p = 0.381), or sex (p = 0.339)
(Table 3). It was particularly noteworthy that lymph node
metastasis was not confirmed histopathologically in any of
the patients with RI B 0. A scattergram showed the SUV-E
and SUV-D values in relation to the presence/absence of
lymph node metastasis (Fig. 1). A significant positive
correlation was observed between the SUV-E and SUV-D
(r = 0.971, P\ 0.001), and none of the all cases with
RI B 0 had lymph node metastasis irrespective of the
SUV-E or SUV-D value.
Histological Characteristics of the cases showing
RI £ 0 on DTP FDG-PET
Table 4 shows the SUV-E, SUV-D, and RI values in
relation to the histological subtype of NSCLC in patients
with RI B 0. The most frequent subtype was lepidic-pre-
dominant invasive adenocarcinoma (n = 24), followed in
frequency by papillary-predominant invasive adenocarci-
noma (n = 8), acinar-predominant invasive adenocarci-
noma (n = 6), invasive mucinous adenocarcinoma
(n = 6), and squamous cell carcinoma (n = 5). The SUV-
E and SUV-D values of acinar-predominant invasive ade-
nocarcinoma and squamous cell carcinoma were higher
than those of lepidic-predominant invasive adenocarci-
noma. The RI of squamous cell carcinoma was higher than
that of lepidic- predominant invasive adenocarcinoma.
Analysis of the prognosis
Univariate analysis identified the age, tumor size, nodal
metastasis, tumor differentiation grade, SUV-E, SUV-D,
and RI as predictors of the RFS. On the other hand, mul-
tivariate analysis using a Cox proportional hazard model
identified only age (P\ 0.001) and nodal metastasis
(P\ 0.001), and the RI (P = 0.023) as independent pre-
dictors of the RFS (Table 5).
Table 1 Patient characteristics (n = 284)
Variable Number %






Squamous cell 71 25.0
Large cell 16 5.6
Others 13 4.6







II(A ? B) 42 14.8





Wedge resection 41 14.4
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Discussion
This study demonstrated that DTP FDG-PET imaging of
the primary tumors can be useful to predict the RFS in
NSCLC patients. In addition, this method may also be
useful to predict the presence of intrathoracic lymph node
metastasis. It was particularly noteworthy that lymph node
metastasis was not confirmed histopathologically in any of
the patients with RI B 0 on DTP FDG-PET. In addition,
we demonstrated that all the cases with SUV-E value of
zero also had SUV-D value of zero. Therefore, delayed
scan can be omitted when the early scan does not show
FDG accumulation in the tumor. This is the first report of
investigation of the significance of decreased FDG uptake
in the pulmonary lesions of NSCLC.
The SUV measured on FDG-PET is a semi-quantita-
tive measure of the degree of glucose uptake in a lesion.
Determination of the SUVmax of primary lung nodules
has been reported to be helpful for distinguishing
between malignant and benign tumors, based on the
relatively higher values in malignant tumors [17]. In
2001, Kubota et al. reported that most malignant lesions,
including primary lung cancers, mediastinal node
metastases, and lymphomas, showed higher FDG uptake
at 2 h than at 1 h after injection of FDG, while normal
tissues and benign lesions, except for sarcoidosis,
showed a lower uptake at 2 h than at 1 h after injection;
they proposed that, therefore, FDG-PET scans obtained
in the delayed-phase show a better sensitivity than the
early-phase images [18]. The SUVmax has been estab-
lished as a powerful predictor of the treatment outcome
in NSCLC patients. However, many factors, such as the
patient preparation method, procedure, scan acquisition
parameters, image reconstruction method, and data
analysis method employed, are known to affect the
SUVmax [19, 20]. For example, Westerterp et al.
described that the reported variations of up to 30 % in
SUV values from 3 institutions could pose a serious
problem when performing multicenter studies [21]. In
fact, differing values of the SUVmax for detecting lymph
node metastasis have been reported from different
studies. To overcome this disadvantage, we used the RI
of the SUVmax using DTP FDG-PET. RI is a relative
scale, and therefore does not require standardization.
Based on these findings, we investigated the impact of RI
on the prognosis in NSCLC patients.
Table 2 Pathological
characteristics in relation to the
SUV-E, SUV-D, and the RI
Characteristics SUV-E SUV-D Retention index (%)
All cases 7.3 ± 5.8 8.9 ± 7.0 21.1 ± 21.6
Histology
Adenocarcinoma 5.4 ± 5.0 6.5 ± 6.1 18.4 ± 18.8
Non-adenocarcinoma 10.9 ± 5.4 13.4 ± 6.3 26.0 ± 25.4
p value \0.001 \0.001 0.010
Tumor differentiation
Well 3.3 ± 3.3 4.0 ± 4.1 15.3 ± 19.0
Moderate/poor 9.2 ± 5.7 11.3 ± 6.9 23.9 ± 22.2
p value \0.001 \0.001 0.001
Tumor size
\30 mm 5.0 ± 4.1 6.2 ± 5.2 22.0 ± 25.4
[31 mm 10.8 ± 6.2 12.9 ± 7.4 19.7 ± 14.2
p value \0.001 \0.001 0.337
Pathological nodal status
Negative 6.6 ± 5.6 8.0 ± 6.9 19.7 ± 19.1
Positive 10.5 ± 5.3 13.0 ± 6.2 27.1 ± 29.4
p value \0.001 \0.001 0.024
Lymphatic invasion
Negative 6.6 ± 6.0 8.0 ± 7.2 20.0 ± 23.2
Positive 9.6 ± 4.6 11.8 ± 5.5 24.5 ± 15.1
p value \0.001 \0.001 0.065
Vascular invasion
Negative 4.8 ± 4.8 5.9 ± 6.0 18.9 ± 25.5
Positive 10.4 ± 5.4 12.7 ± 6.3 23.8 ± 15.1
p value \0.001 \0.001 0.045
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Three steps are involved in the 18-F FDG accumulation
in cancer cells: (1) facilitated diffusion through glucose
transport proteins; (2) subsequent phosphorylation by
hexokinase isoforms producing FDG-6-phosphate; (3)
decreased dephosphorylation [22]. Thus, 18-F FDG accu-
mulation depends basically on the rate of transport through
the cell membrane and the activity of hexokinase. Theo-
retically, the ratio of hexokinase to FDG-6-phosphatase
more specifically increases in tumors than in inflammatory
lesions, resulting in a gradual accumulation of FDG and a
further increase of the SUV on delayed imaging. Therefore,
RI may be a better indicator of the malignant potential,
whereas the SUV-E represents malignant potential of a
tumor [23]. Thus, being a possibly better indicator of
malignant potential, RI might be a predictor of the risk of
nodal metastasis.
Evaluation of lymph node metastases is important for
the staging of lung cancer and for the selection of the most
appropriate therapy. Since FDG-PET has been shown to be
superior to CT for evaluation of the lymph node status in
patients with NSCLC, FDG-PET has been increasingly
used worldwide [24, 25]. In general, the lymph node status
is interpreted qualitatively or quantitatively on FDG-PET
scans, based on the tendency towards a higher FDG uptake
in metastatic lymph nodes than in non-metastatic lymph
nodes [24, 25]. In addition, recently, several investigators
have introduced DTP FDG-PET to improve the accuracy of
FDG-PET for nodal staging in cases of NSCLC [11–13].
Based on the results of previous studies, it is known that
malignant tumors exhibit increased FDG uptake for several
hours, while benign lesions show decreased FDG uptake on
DTP FDG-PET [9, 21]. While studies have generally
shown favorable accuracy of this modality for nodal stag-
ing, this method is rather cumbersome for examining all of
the lymph nodes showing FDG accumulation. In this study,
we evaluated the primary tumors in NSCLC patients by
DTP FDG-PET, which is a simpler and more accurate
method than imaging of the number of lymph nodes
involved.
To date, DTP FDG-PET has mainly been utilized to
improve the accuracy of diagnosis of lung nodules or
lymph nodes. Recently, few reports have addressed the
possible usefulness of RI in predicting the risk of recur-
rence or prognosis. Kim et al. reported that RI proved
inadequate for predicting the prognosis in terms of the OS
and disease-free survival in early stage (stage I and II)
NSCLC patients treated by surgical resection [26]. On the
other hand, Satoh et al. reported that a higher value of the
Table 3 Clinico-pathological characteristics in relation to the RI
Characteristics N RI B 0 RI[ 0 P value
Patients (number) 284 49 235
SUV-E (mean) 2.2 8.4 \0.001
SUV-D (mean) 2.0 10.4 \0.001
Age (mean), year 69.5 70.6 0.381
Sex
Male 195 31 164 0.399
Female 89 18 71
Histology \0.001
Adenocarcinoma 184 44 140
Non-adenocarcinoma 100 5 95
Tumor size (mean), mm 22.5 30.5 0.001
Pathological nodal status \0.001
Negative 230 49 181
Positive 54 0 54
Tumor differentiation \0.001
Well 92 34 58
Moderate 110 12 98
Poor 82 3 79
Pleural invasion \0.001
Negative 185 44 141
Positive 99 5 94
Lymphatic invasion \0.001
Negative 214 47 167
Positive 70 2 68
Vascular invasion
Negative 157 44 113 \0.001
Positive 127 5 122
Fig. 1 A scattergram showed that a significant positive correlation
was observed between the SUV-E and SUV-D (r = 0.971,
P\ 0.001), and none of the all cases with RI B 0 had lymph node
metastasis
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RI significantly predicted a higher risk of distant metastasis
in stage I NSCLC patients treated by stereotactic body
radiation. They suggested that the RI tended to predict
lower risk of local recurrence and lymph node metastasis
[23]. We also demonstrated the prognostic value of DTP
FDG-PET for the RFS or OS in NSCLC patients.
This study has several limitations that should be con-
sidered when interpreting the results. The retrospective
study design was a major limitation. Minor limitations
included insufficient evidence of the validity of the
115 min of delayed acquisition and the cut-off value for RI.
Conclusion
In conclusion, this study demonstrated that DTP FDG-PET
imaging of the primary tumors in patients with NSCLC can
be useful to predict the RFS in these patients. In addition,
this method may also be useful to predict the presence/
absence of intrathoracic lymph node metastasis.
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